<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03699241</url>
  </required_header>
  <id_info>
    <org_study_id>IAVI W001</org_study_id>
    <nct_id>NCT03699241</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults</brief_title>
  <official_title>A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International AIDS Vaccine Initiative</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fred Hutchinson Cancer Research Center - Seattle HIV Vaccine Trials Unit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kenya AIDS Vaccine Initiative - Institute of Clinical Research (KAVI-ICR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>International AIDS Vaccine Initiative</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This a phase 1 first-in-human clinical trial to evaluate the safety, tolerability, and
      immunogenicity of BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in up to 60 healthy adult
      HIV-uninfected volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This a phase 1 first-in-human clinical trial to evaluate the safety, tolerability, and
      immunogenicity of BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in up to 60 healthy adult
      HIV-uninfected volunteers. BG505 SOSIP.664 gp140 is a stable, soluble, cleaved HIV envelope
      trimer formulated in 0.55mL at 2mg/mL in 20 mM Tris, 100 mM NaCl, pH 7.5 and will be
      administered IM.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 3, 2018</start_date>
  <completion_date type="Anticipated">May 20, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 20, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of volunteers with moderate or greater reactogenicity (i.e., solicited adverse events) during a 7-day follow-up period after each vaccination</measure>
    <time_frame>7 days post-vaccination</time_frame>
    <description>To evaluate the safety and tolerability of the study regimens based on the frequency of local and systemic reactogenicity events as assessed using the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (v2.1).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of volunteers with moderate or greater and/or vaccine related unsolicited adverse events (AEs), including safety laboratory (biochemical, haematological) parameters, from the day of each vaccination up to 28 days post each vaccination</measure>
    <time_frame>28 days post-vaccination</time_frame>
    <description>To evaluate the safety and tolerability of the study regimens based on the proportion of volunteers with moderate or greater unsolicited adverse events including safety laboratory as assessed using the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (v2.1).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of volunteers with vaccine-related serious adverse events (SAEs) throughout the study period</measure>
    <time_frame>18 months</time_frame>
    <description>To evaluate the safety and tolerability of the study regimens based on the proportion of volunteers with vaccine-related serious adverse events including safety laboratory as assessed using the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (v2.1).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of volunteers in each group with potential immune-mediated diseases (pIMD) from the day of injection throughout the study period</measure>
    <time_frame>18 months</time_frame>
    <description>To evaluate the proportion of volunteers in each group with potential immune-mediated diseases (pIMDs) based on a defined list of pIMDs in the study protocol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess immune responses elicited by the different BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, doses:</measure>
    <time_frame>20 months</time_frame>
    <description>Proportion of volunteers with neutralizing antibodies against autologous BG505 SOSIP.664 gp140 Vaccine, Adjuvanted</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess immune responses elicited by the different BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, doses:</measure>
    <time_frame>20 months</time_frame>
    <description>Proportion of volunteers with and magnitude of trimer binding antibodies to BG505 SOSIP.664 gp140 Vaccine, Adjuvanted</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess immune responses elicited by the different BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, doses:</measure>
    <time_frame>20 months</time_frame>
    <description>Proportion of volunteers with neutralizing antibodies against additional viral strains (e.g., Tier 1a/b, Tier 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess immune responses elicited by the different BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, doses:</measure>
    <time_frame>20 months</time_frame>
    <description>Proportion of volunteers with and magnitude of binding antibodies to HIV Env</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess immune responses elicited by the different BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, doses:</measure>
    <time_frame>20 months</time_frame>
    <description>Proportion of volunteers with HIV Env specific B and T-cell responses</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>HIV-Uninfected participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>HIV-Uninfected participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>HIV-Uninfected participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>HIV-Uninfected participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>HIV-Uninfected participants</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BG505 SOSIP.664 gp140, adjuvanted</intervention_name>
    <description>Dosage of 30ug, Intramuscular administration</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BG505 SOSIP.664 gp140, adjuvanted</intervention_name>
    <description>Dosage of 100ug, Intramuscular administration</description>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BG505 SOSIP.664 gp140, adjuvanted</intervention_name>
    <description>Dosage of 300ug, Intramuscular administration</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tris-NaCl Diluent</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male and female, including transgender individuals, as assessed by a medical
             history, physical exam, and laboratory tests

          2. At least 18 years of age on the day of screening and has not reached his/her 51st
             birthday on the day of first vaccination

          3. Willing to comply with the requirements of the protocol and available for follow-up
             for the planned duration of the study

          4. In the opinion of the Principal Investigator or designee and based on Assessment of
             Informed Consent Understanding results, has understood the information provided and
             potential impact and/or risks linked to vaccination and participation in the trial;
             written informed consent will be obtained from the volunteer before any study-related
             procedures are performed

          5. Willing to undergo HIV testing, risk reduction counselling and receive HIV test
             results

          6. All volunteers born female engaging in sexual activity that could lead to pregnancy
             must commit to use an effective method of contraception for 4 months following
             investigational product administration

          7. All volunteers born female, who are not heterosexually active at screening, must agree
             to utilize an effective method of contraception if they become heterosexually active

          8. All volunteers born female must be willing to undergo urine pregnancy tests at time
             points indicated in the Schedule of Procedures (Appendix A and B)

          9. All sexually active volunteers born male, regardless of reproductive potential, must
             be willing to use an effective method of contraception (such as consistent condom use)
             from the day of first vaccination until at least 4 months after the last vaccination
             to avoid exposure of partners to investigational product in ejaculate and to prevent
             conception with female partners

         10. Willing to forgo donations of blood, or any other tissues during the study and, for
             those who test HIV-positive due to vaccine-induced antibodies, until the anti-HIV
             antibody titers become undetectable

        Exclusion Criteria:

          1. Confirmed HIV-1 or HIV-2 infection

          2. Any clinically relevant abnormality on history or examination including history of
             immunodeficiency or autoimmune disease; use of corticosteroids (the use of topical,
             nasal, or inhaled steroids is permitted), immunosuppressive, anticancer,
             anti-tuberculosis or other medications considered significant by the investigator
             within the previous 6 months. The following exceptions are permitted and will not
             exclude study participation: use of corticosteroid nasal spray for rhinitis, topical
             corticosteroids for an acute uncomplicated dermatitis; or a short course (duration of
             10 days or less, or a single injection) of corticosteroid for a non-chronic condition
             (based on investigator clinical judgment) at least 2 weeks prior to enrolment in this
             study

          3. Any clinically significant acute or chronic medical condition that is considered
             progressive or in the opinion of the investigator makes the volunteer unsuitable for
             participation in the study

          4. Reported risky behavior for HIV infection within 12 months prior to vaccination

          5. If female, pregnant or planning a pregnancy during the period of enrolment until 4
             months after the last study vaccination; or lactating

          6. Bleeding disorder that was diagnosed by a physician (e.g., factor deficiency,
             coagulopathy or platelet disorder that requires special precautions.) (Note: A
             volunteer who states that he or she has easy bruising or bleeding, but does not have a
             formal diagnosis and has IM injections and blood draws without any adverse experience,
             is eligible)

          7. Infectious disease: chronic hepatitis B infection (HbsAg-positive), current hepatitis
             C infection (for US sites: HCV Ab positive and HCV RNA positive, for African site: HCV
             Ab positive only) treatment for chronic hepatitis C infection in the past year, or
             active syphilis (positive RPR confirmed by TPHA); active tuberculosis (for African
             site only)

          8. History of splenectomy

          9. Any of the following abnormal laboratory parameters listed below:

             Hematology

               -  Absolute Neutrophil Count (ANC) - all volunteers: ≤1,000/mm3

               -  Absolute Lymphocyte Count (ALC) - all volunteers: ≤650/mm3

               -  Hemoglobin - African volunteers: &lt;9.5 g/dl in females; &lt;11.0 g/dl in males

               -  Hemoglobin - US volunteers: &lt;10.5 g/dl in females; &lt;11.0 g/dl in males

               -  Platelets - African volunteers: &lt;100,000 cells/mm3

               -  Platelets - US volunteers: &lt;125,000 cells/mm3

             Chemistry

               -  Creatinine &gt;1.1 x upper limit of normal (ULN)

               -  ALT &gt;1.25 x ULN

               -  AST &gt;1.25 x ULN

             Urinalysis

             Clinically significant abnormal dipstick confirmed by microscopy:

               -  Protein = 1+ or more

               -  Blood = 2+ or more (not due to menses)

         10. Receipt of live attenuated vaccine within the previous 30 days or planned receipt
             within 30 days after vaccination with Investigational Product; or receipt of other
             vaccine within the previous 14 days or planned receipt within 14 days after
             vaccination with Investigational Product. (Exception is live attenuated influenza
             vaccine within 14 days)

         11. Receipt of blood transfusion or blood-derived products within the previous 3 months

         12. Participation in another clinical trial of an Investigational Product currently,
             within the previous 3 months or expected participation during this study; Concurrent
             participation in an observational study not requiring any blood or tissue sample
             collection is not an exclusion

         13. Prior receipt of another investigational HIV vaccine candidate or HIV monoclonal
             antibody (Note: receipt of placebo in a previous HIV vaccine trial will not exclude a
             volunteer from participation if documentation is available and the Medical Monitor
             gives approval)

         14. History of severe local or systemic reactogenicity to vaccines (e.g., anaphylaxis,
             respiratory difficulties, angioedema, injection site necrosis or ulceration)

         15. Psychiatric condition that compromises safety of the volunteer and precludes
             compliance with the protocol. Specifically excluded are persons with psychoses within
             the past 3 years prior to screening, ongoing risk for suicide, or history of suicide
             attempt or gesture within the past 3 years

         16. Seizure disorder: A participant who has had a seizure in the last 3 years prior to
             screening is excluded. (Not excluded: a participant with a history of seizures who has
             neither required medications nor had a seizure for 3 years)

         17. A history of malignancy in the past 5 years (prior to screening) or ongoing malignancy
             (A history of a completely excised malignancy that is considered cured is not an
             exclusion)

         18. Active, serious infections requiring parenteral antibiotic, antiviral or antifungal
             therapy within 30 days prior to enrolment

         19. Body mass index (BMI) ≥35

         20. Body weight &lt;110 pounds (55 kg); for US sites only

         21. If, in the opinion of the Principal Investigator, it is not in the best interest of
             the volunteer to participate in the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie McElrath, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seattle HIV Vaccine Trials Unit</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Omu Anzala, MBChB, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kenya AIDS Vaccine Initiative - Institute of Clinical Research (KAVI-ICR)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Boris Juelg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dagna Laufer, MD</last_name>
    <phone>1-212-328-7459</phone>
    <email>dlaufer@iavi.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>MGH</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Louis</last_name>
      <phone>425-610-6448</phone>
      <email>info@seattlevaccines.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kenya AIDS Vaccine Initiative</name>
      <address>
        <city>Nairobi</city>
        <country>Kenya</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Omu Anzala, MBChB, PhD</last_name>
      <phone>+254 202 714 613</phone>
      <email>oanzala@kaviuon.org</email>
    </contact>
    <investigator>
      <last_name>Omu Anzala, MBChB, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Kenya</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://iavi.org</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>October 3, 2018</study_first_submitted>
  <study_first_submitted_qc>October 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2018</study_first_posted>
  <last_update_submitted>July 25, 2019</last_update_submitted>
  <last_update_submitted_qc>July 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

